Gossamer Bio, Inc. (GOSS) 10-Year Financial Performance & Capital Metrics

GOSS • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutGossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Show more

Revenue $115M
EBITDA -$56M +68.9%
Net Income -$57M +68.6%
EPS (Diluted) -0.25 +78.8%
Gross Margin 100%
EBITDA Margin -48.62%
Operating Margin -52.24%
Net Margin -49.28%
ROE -122.54% +74.5%
ROIC -20.93% +72.0%
Debt/Equity 6.88 +103.2%
Interest Coverage -5.20 +61.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 86 (top 14%)

✗Weaknesses

✗High debt to equity ratio of 6.9x
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Expensive at 18.8x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-58.17%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-117.96%

EPS CAGR

10Y-

5Y-

3Y-

TTM-109.09%

ROCE

10Y Avg-68.61%

5Y Avg-56.51%

3Y Avg-60.52%

Latest-22.59%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	114.7M
Revenue Growth %	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	297K	3.09M	4.27M	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	-297K	-3.09M	-4.27M	0	0	0	114.7M
Gross Margin %	-	-	-	-	-	-	-	-	1%
Gross Profit Growth %	-	-	-	-9.4%	-0.38%	1%	-	-	-
Operating Expenses+	83K	1.15M	99.33M	182.54M	206.31M	216.12M	218.59M	183.76M	174.62M
OpEx % of Revenue	-	-	-	-	-	-	-	-	1.52%
Selling, General & Admin	83K	262K	44.05M	39.14M	48.32M	45.78M	47.61M	38.45M	36.13M
SG&A % of Revenue	-	-	-	-	-	-	-	-	0.32%
Research & Development	0	891K	55.28M	143.4M	158M	170.27M	170.92M	135.3M	138.49M
R&D % of Revenue	-	-	-	-	-	-	-	-	1.21%
Other Operating Expenses	0	0	316K	5.83M	0	75K	65K	10M	0
Operating Income+	-83K	-6.65M	-148.99M	-186.14M	-210.58M	-216.12M	-218.59M	-183.76M	-59.92M
Operating Margin %	-	-	-	-	-	-	-	-	-0.52%
Operating Income Growth %	-	-79.16%	-21.39%	-0.25%	-0.13%	-0.03%	-0.01%	0.16%	0.67%
EBITDA+	0	-5.5M	-148.7M	-183.05M	-206.31M	-210.96M	-214.16M	-179.37M	-55.77M
EBITDA Margin %	-	-	-	-	-	-	-	-	-0.49%
EBITDA Growth %	-	-	-26.04%	-0.23%	-0.13%	-0.02%	-0.02%	0.16%	0.69%
D&A (Non-Cash Add-back)	83K	1.15M	297K	3.09M	4.27M	5.17M	4.43M	4.38M	4.15M
EBIT	-83K	-6.65M	-146.96M	-182.54M	-230.69M	-214.56M	-215.5M	-166.31M	-44.12M
Net Interest Income+	0	0	1.71M	0	-9.22M	-18.68M	-12.3M	-11.51M	-9.74M
Interest Income	0	0	1.72M	0	3.44M	761K	1.58M	2M	1.78M
Interest Expense	0	118K	12K	0	12.67M	19.44M	13.88M	13.51M	11.52M
Other Income/Expense	0	-118K	2.02M	5.83M	-32.78M	-17.88M	-10.79M	3.94M	4.28M
Pretax Income+	-83K	-6.77M	-146.97M	-180.31M	-243.36M	-234M	-229.38M	-179.82M	-55.63M
Pretax Margin %	-	-	-	-	-	-	-	-	-0.49%
Income Tax+	0	0	0	0	0	0	0	0	893K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1.02%
Net Income+	-83K	-6.77M	-146.97M	-180.82M	-243.36M	-234M	-229.38M	-179.82M	-56.53M
Net Margin %	-	-	-	-	-	-	-	-	-0.49%
Net Income Growth %	-	-80.58%	-20.71%	-0.23%	-0.35%	0.04%	0.02%	0.22%	0.69%
Net Income (Continuing)	-83K	-6.77M	-146.97M	-180.31M	-243.36M	-234M	-229.38M	-179.82M	-56.53M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.01	-0.27	-2.43	-3.30	-3.67	-3.33	-2.84	-1.18	-0.25
EPS Growth %	-	-	-8%	-0.36%	-0.11%	0.09%	0.15%	0.58%	0.79%
EPS (Basic)	-0.01	-0.27	-2.43	-3.30	-3.67	-3.33	-2.84	-0.80	-0.25
Diluted Shares Outstanding	9.16M	24.83M	60.4M	54.74M	68.51M	74.84M	84.57M	225.57M	226.23M
Basic Shares Outstanding	9.16M	24.83M	60.4M	54.74M	68.51M	74.84M	84.57M	225.57M	226.23M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	60K	445K	231.95M	409.32M	522.32M	331.78M	261.88M	306.52M	309.89M
Cash & Short-Term Investments	60K	315K	228.66M	401.77M	512.63M	325.22M	255.68M	296.43M	294.52M
Cash Only	60K	315K	105.22M	135.03M	486.06M	183.4M	111.97M	32.11M	46.07M
Short-Term Investments	0	0	123.44M	266.74M	26.57M	141.81M	143.71M	264.32M	248.44M
Accounts Receivable	0	0	0	0	0	0	0	0	5.34M
Days Sales Outstanding	-	-	-	-	-	-	-	-	16.99
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	700K	63K	565K	64K	0	10.09M	10.03M
Total Non-Current Assets+	0	0	7.47M	17.29M	17.11M	11.88M	10.57M	5.4M	5.4M
Property, Plant & Equipment	0	0	3.19M	15.73M	16.08M	10.8M	9.89M	4.78M	5.12M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	22.40x
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	4.27M	1.56M	1.03M	1.08M	680K	618K	283K
Total Assets+	60K	445K	239.42M	426.6M	539.43M	343.66M	272.45M	311.92M	315.29M
Asset Turnover	-	-	-	-	-	-	-	-	0.36x
Asset Growth %	-	6.42%	537.02%	0.78%	0.26%	-0.36%	-0.21%	0.14%	0.01%
Total Current Liabilities+	143K	1.27M	20.4M	36.92M	38.65M	39.86M	49.23M	51.6M	45.01M
Accounts Payable	40K	97K	2.18M	956K	7.51M	3.24M	1.46M	5.53M	2.32M
Days Payables Outstanding	-	-	2.68K	112.96	642.09	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	11.61M	11.61M	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	1000K
Other Current Liabilities	0	0	0	9.28M	12.19M	11.92M	13.53M	10.29M	0
Current Ratio	0.42x	0.35x	11.37x	11.09x	13.51x	8.32x	5.32x	5.94x	6.88x
Quick Ratio	0.42x	0.35x	11.37x	11.09x	13.51x	8.32x	5.32x	5.94x	6.88x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	40K	6.04M	339.08M	37.2M	180.1M	182.34M	211.14M	197.55M	240.79M
Long-Term Debt	40K	6.04M	0	28.46M	172.39M	179.12M	207.7M	197.41M	197.52M
Capital Lease Obligations	0	0	0	8.74M	7.71M	3.22M	3.45M	144K	4.4M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	1K	339.08M	0	0	0	0	0	0
Total Liabilities	183K	7.31M	359.49M	74.12M	218.75M	222.19M	260.37M	249.15M	285.8M
Total Debt+	40K	6.04M	0	39.55M	183.73M	185.24M	225.74M	212.46M	202.88M
Net Debt	-20K	5.72M	-105.22M	-95.48M	-302.32M	1.83M	113.77M	180.35M	156.81M
Debt / Equity	-	-	-	0.11x	0.57x	1.53x	18.69x	3.38x	6.88x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-56.38x	-12416.08x	-	-16.63x	-11.12x	-15.75x	-13.60x	-5.20x
Total Equity+	-123K	-6.86M	-120.07M	352.49M	320.68M	121.46M	12.08M	62.77M	29.49M
Equity Growth %	-	-54.79%	-16.5%	3.94%	-0.09%	-0.62%	-0.9%	4.2%	-0.53%
Book Value per Share	-0.01	-0.28	-1.99	6.44	4.68	1.62	0.14	0.28	0.13
Total Shareholders' Equity	-123K	-6.86M	-120.07M	352.49M	320.68M	121.46M	12.08M	62.77M	29.49M
Common Stock	0	0	2K	7K	8K	8K	10K	23K	23K
Retained Earnings	-123K	-6.89M	-153.86M	-334.17M	-577.53M	-811.53M	-1.03B	-1.21B	-1.27B
Treasury Stock	0	0	-4.65M	0	0	0	0	0	0
Accumulated OCI	0	0	-61K	258K	599K	45K	-574K	-350K	1.19M
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	20K	-5.75M	-51.04M	-144.83M	-176.36M	-188.89M	-187.03M	-159.16M	-3.47M
Operating CF Margin %	-	-	-	-	-	-	-	-	-0.03%
Operating CF Growth %	-	-288.25%	-7.88%	-1.84%	-0.22%	-0.07%	0.01%	0.15%	0.98%
Net Income	-83K	-6.77M	-146.97M	-180.31M	-243.36M	-234M	-229.38M	-179.82M	-56.53M
Depreciation & Amortization	0	0	297K	3.09M	4.27M	5.17M	4.43M	4.38M	4.15M
Stock-Based Compensation	0	32K	30.95M	20.82M	38.75M	32.01M	42.55M	28.52M	20.62M
Deferred Taxes	0	0	0	0	-158K	0	0	0	0
Other Non-Cash Items	103K	32K	49.66M	1.45M	27.24M	7.17M	-177K	2.6M	-11.17M
Working Capital Changes	103K	994K	15.02M	10.12M	-3.1M	774K	-4.46M	-14.84M	39.46M
Change in Receivables	0	0	0	0	0	0	0	0	-5.34M
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	103K	57K	2.08M	-1.4M	6.98M	-4.43M	-1.81M	3.99M	-1.66M
Cash from Investing+	0	0	-144.71M	-147.14M	215.34M	-117.43M	-1.03M	-110.97M	29.02M
Capital Expenditures	0	0	-21.21M	-2.97M	-24.88M	-1.55M	-475K	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	17.72M	-3.6M	-23.38M	-75K	65K	0	0
Cash from Financing+	40K	6M	300.86M	321.58M	312.54M	3.33M	117.09M	190.15M	-11.49M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	0	0	-2.14M	2.04M	1.83M	3.33M	2.95M	444K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	20K	-5.75M	-72.25M	-151.4M	-201.24M	-190.51M	-187.51M	-159.16M	-3.47M
FCF Margin %	-	-	-	-	-	-	-	-	-0.03%
FCF Growth %	-	-288.25%	-11.58%	-1.1%	-0.33%	0.05%	0.02%	0.15%	0.98%
FCF per Share	0.00	-0.23	-1.20	-2.77	-2.94	-2.55	-2.22	-0.71	-0.02
FCF Conversion (FCF/Net Income)	-0.24x	0.85x	0.35x	0.80x	0.72x	0.81x	0.82x	0.89x	0.06x
Interest Paid	0	0	0	1.48M	0	12.74M	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-155.6%	-72.3%	-105.85%	-343.53%	-480.5%	-122.54%
Return on Invested Capital (ROIC)	-	-	-	-880.2%	-114.71%	-228.85%	-131.61%	-74.71%	-20.93%
Gross Margin	-	-	-	-	-	-	-	-	100%
Net Margin	-	-	-	-	-	-	-	-	-49.28%
Debt / Equity	-	-	-	0.11x	0.57x	1.53x	18.69x	3.38x	6.88x
Interest Coverage	-	-56.38x	-12416.08x	-	-16.63x	-11.12x	-15.75x	-13.60x	-5.20x
FCF Conversion	-0.24x	0.85x	0.35x	0.80x	0.72x	0.81x	0.82x	0.89x	0.06x

Revenue by Segment

	2024
License and Service	90.68M
License and Service Growth	-

Frequently Asked Questions

Growth & Financials

Gossamer Bio, Inc. (GOSS) reported $44.1M in revenue for fiscal year 2024.

Gossamer Bio, Inc. (GOSS) grew revenue by 0.0% over the past year. Growth has been modest.

Gossamer Bio, Inc. (GOSS) reported a net loss of $156.2M for fiscal year 2024.

Dividend & Returns

Gossamer Bio, Inc. (GOSS) has a return on equity (ROE) of -122.5%. Negative ROE indicates the company is unprofitable.

Gossamer Bio, Inc. (GOSS) had negative free cash flow of $158.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Gossamer Bio, Inc. (GOSS) 10-Year Financial Performance & Capital Metrics

GOSS • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $115M
EBITDA -$56M +68.9%
Net Income -$57M +68.6%
EPS (Diluted) -0.25 +78.8%
Gross Margin 100%
EBITDA Margin -48.62%
Operating Margin -52.24%
Net Margin -49.28%
ROE -122.54% +74.5%
ROIC -20.93% +72.0%
Debt/Equity 6.88 +103.2%
Interest Coverage -5.20 +61.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 86 (top 14%)

✗Weaknesses

✗High debt to equity ratio of 6.9x
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Expensive at 18.8x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-58.17%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-117.96%

EPS CAGR

10Y-

5Y-

3Y-

TTM-109.09%

ROCE

10Y Avg-68.61%

5Y Avg-56.51%

3Y Avg-60.52%

Latest-22.59%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	114.7M
Revenue Growth %	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	297K	3.09M	4.27M	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	-297K	-3.09M	-4.27M	0	0	0	114.7M
Gross Margin %	-	-	-	-	-	-	-	-	1%
Gross Profit Growth %	-	-	-	-9.4%	-0.38%	1%	-	-	-
Operating Expenses+	83K	1.15M	99.33M	182.54M	206.31M	216.12M	218.59M	183.76M	174.62M
OpEx % of Revenue	-	-	-	-	-	-	-	-	1.52%
Selling, General & Admin	83K	262K	44.05M	39.14M	48.32M	45.78M	47.61M	38.45M	36.13M
SG&A % of Revenue	-	-	-	-	-	-	-	-	0.32%
Research & Development	0	891K	55.28M	143.4M	158M	170.27M	170.92M	135.3M	138.49M
R&D % of Revenue	-	-	-	-	-	-	-	-	1.21%
Other Operating Expenses	0	0	316K	5.83M	0	75K	65K	10M	0
Operating Income+	-83K	-6.65M	-148.99M	-186.14M	-210.58M	-216.12M	-218.59M	-183.76M	-59.92M
Operating Margin %	-	-	-	-	-	-	-	-	-0.52%
Operating Income Growth %	-	-79.16%	-21.39%	-0.25%	-0.13%	-0.03%	-0.01%	0.16%	0.67%
EBITDA+	0	-5.5M	-148.7M	-183.05M	-206.31M	-210.96M	-214.16M	-179.37M	-55.77M
EBITDA Margin %	-	-	-	-	-	-	-	-	-0.49%
EBITDA Growth %	-	-	-26.04%	-0.23%	-0.13%	-0.02%	-0.02%	0.16%	0.69%
D&A (Non-Cash Add-back)	83K	1.15M	297K	3.09M	4.27M	5.17M	4.43M	4.38M	4.15M
EBIT	-83K	-6.65M	-146.96M	-182.54M	-230.69M	-214.56M	-215.5M	-166.31M	-44.12M
Net Interest Income+	0	0	1.71M	0	-9.22M	-18.68M	-12.3M	-11.51M	-9.74M
Interest Income	0	0	1.72M	0	3.44M	761K	1.58M	2M	1.78M
Interest Expense	0	118K	12K	0	12.67M	19.44M	13.88M	13.51M	11.52M
Other Income/Expense	0	-118K	2.02M	5.83M	-32.78M	-17.88M	-10.79M	3.94M	4.28M
Pretax Income+	-83K	-6.77M	-146.97M	-180.31M	-243.36M	-234M	-229.38M	-179.82M	-55.63M
Pretax Margin %	-	-	-	-	-	-	-	-	-0.49%
Income Tax+	0	0	0	0	0	0	0	0	893K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1.02%
Net Income+	-83K	-6.77M	-146.97M	-180.82M	-243.36M	-234M	-229.38M	-179.82M	-56.53M
Net Margin %	-	-	-	-	-	-	-	-	-0.49%
Net Income Growth %	-	-80.58%	-20.71%	-0.23%	-0.35%	0.04%	0.02%	0.22%	0.69%
Net Income (Continuing)	-83K	-6.77M	-146.97M	-180.31M	-243.36M	-234M	-229.38M	-179.82M	-56.53M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.01	-0.27	-2.43	-3.30	-3.67	-3.33	-2.84	-1.18	-0.25
EPS Growth %	-	-	-8%	-0.36%	-0.11%	0.09%	0.15%	0.58%	0.79%
EPS (Basic)	-0.01	-0.27	-2.43	-3.30	-3.67	-3.33	-2.84	-0.80	-0.25
Diluted Shares Outstanding	9.16M	24.83M	60.4M	54.74M	68.51M	74.84M	84.57M	225.57M	226.23M
Basic Shares Outstanding	9.16M	24.83M	60.4M	54.74M	68.51M	74.84M	84.57M	225.57M	226.23M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	60K	445K	231.95M	409.32M	522.32M	331.78M	261.88M	306.52M	309.89M
Cash & Short-Term Investments	60K	315K	228.66M	401.77M	512.63M	325.22M	255.68M	296.43M	294.52M
Cash Only	60K	315K	105.22M	135.03M	486.06M	183.4M	111.97M	32.11M	46.07M
Short-Term Investments	0	0	123.44M	266.74M	26.57M	141.81M	143.71M	264.32M	248.44M
Accounts Receivable	0	0	0	0	0	0	0	0	5.34M
Days Sales Outstanding	-	-	-	-	-	-	-	-	16.99
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	700K	63K	565K	64K	0	10.09M	10.03M
Total Non-Current Assets+	0	0	7.47M	17.29M	17.11M	11.88M	10.57M	5.4M	5.4M
Property, Plant & Equipment	0	0	3.19M	15.73M	16.08M	10.8M	9.89M	4.78M	5.12M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	22.40x
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	4.27M	1.56M	1.03M	1.08M	680K	618K	283K
Total Assets+	60K	445K	239.42M	426.6M	539.43M	343.66M	272.45M	311.92M	315.29M
Asset Turnover	-	-	-	-	-	-	-	-	0.36x
Asset Growth %	-	6.42%	537.02%	0.78%	0.26%	-0.36%	-0.21%	0.14%	0.01%
Total Current Liabilities+	143K	1.27M	20.4M	36.92M	38.65M	39.86M	49.23M	51.6M	45.01M
Accounts Payable	40K	97K	2.18M	956K	7.51M	3.24M	1.46M	5.53M	2.32M
Days Payables Outstanding	-	-	2.68K	112.96	642.09	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	11.61M	11.61M	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	1000K
Other Current Liabilities	0	0	0	9.28M	12.19M	11.92M	13.53M	10.29M	0
Current Ratio	0.42x	0.35x	11.37x	11.09x	13.51x	8.32x	5.32x	5.94x	6.88x
Quick Ratio	0.42x	0.35x	11.37x	11.09x	13.51x	8.32x	5.32x	5.94x	6.88x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	40K	6.04M	339.08M	37.2M	180.1M	182.34M	211.14M	197.55M	240.79M
Long-Term Debt	40K	6.04M	0	28.46M	172.39M	179.12M	207.7M	197.41M	197.52M
Capital Lease Obligations	0	0	0	8.74M	7.71M	3.22M	3.45M	144K	4.4M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	1K	339.08M	0	0	0	0	0	0
Total Liabilities	183K	7.31M	359.49M	74.12M	218.75M	222.19M	260.37M	249.15M	285.8M
Total Debt+	40K	6.04M	0	39.55M	183.73M	185.24M	225.74M	212.46M	202.88M
Net Debt	-20K	5.72M	-105.22M	-95.48M	-302.32M	1.83M	113.77M	180.35M	156.81M
Debt / Equity	-	-	-	0.11x	0.57x	1.53x	18.69x	3.38x	6.88x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-56.38x	-12416.08x	-	-16.63x	-11.12x	-15.75x	-13.60x	-5.20x
Total Equity+	-123K	-6.86M	-120.07M	352.49M	320.68M	121.46M	12.08M	62.77M	29.49M
Equity Growth %	-	-54.79%	-16.5%	3.94%	-0.09%	-0.62%	-0.9%	4.2%	-0.53%
Book Value per Share	-0.01	-0.28	-1.99	6.44	4.68	1.62	0.14	0.28	0.13
Total Shareholders' Equity	-123K	-6.86M	-120.07M	352.49M	320.68M	121.46M	12.08M	62.77M	29.49M
Common Stock	0	0	2K	7K	8K	8K	10K	23K	23K
Retained Earnings	-123K	-6.89M	-153.86M	-334.17M	-577.53M	-811.53M	-1.03B	-1.21B	-1.27B
Treasury Stock	0	0	-4.65M	0	0	0	0	0	0
Accumulated OCI	0	0	-61K	258K	599K	45K	-574K	-350K	1.19M
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	20K	-5.75M	-51.04M	-144.83M	-176.36M	-188.89M	-187.03M	-159.16M	-3.47M
Operating CF Margin %	-	-	-	-	-	-	-	-	-0.03%
Operating CF Growth %	-	-288.25%	-7.88%	-1.84%	-0.22%	-0.07%	0.01%	0.15%	0.98%
Net Income	-83K	-6.77M	-146.97M	-180.31M	-243.36M	-234M	-229.38M	-179.82M	-56.53M
Depreciation & Amortization	0	0	297K	3.09M	4.27M	5.17M	4.43M	4.38M	4.15M
Stock-Based Compensation	0	32K	30.95M	20.82M	38.75M	32.01M	42.55M	28.52M	20.62M
Deferred Taxes	0	0	0	0	-158K	0	0	0	0
Other Non-Cash Items	103K	32K	49.66M	1.45M	27.24M	7.17M	-177K	2.6M	-11.17M
Working Capital Changes	103K	994K	15.02M	10.12M	-3.1M	774K	-4.46M	-14.84M	39.46M
Change in Receivables	0	0	0	0	0	0	0	0	-5.34M
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	103K	57K	2.08M	-1.4M	6.98M	-4.43M	-1.81M	3.99M	-1.66M
Cash from Investing+	0	0	-144.71M	-147.14M	215.34M	-117.43M	-1.03M	-110.97M	29.02M
Capital Expenditures	0	0	-21.21M	-2.97M	-24.88M	-1.55M	-475K	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	17.72M	-3.6M	-23.38M	-75K	65K	0	0
Cash from Financing+	40K	6M	300.86M	321.58M	312.54M	3.33M	117.09M	190.15M	-11.49M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	0	0	-2.14M	2.04M	1.83M	3.33M	2.95M	444K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	20K	-5.75M	-72.25M	-151.4M	-201.24M	-190.51M	-187.51M	-159.16M	-3.47M
FCF Margin %	-	-	-	-	-	-	-	-	-0.03%
FCF Growth %	-	-288.25%	-11.58%	-1.1%	-0.33%	0.05%	0.02%	0.15%	0.98%
FCF per Share	0.00	-0.23	-1.20	-2.77	-2.94	-2.55	-2.22	-0.71	-0.02
FCF Conversion (FCF/Net Income)	-0.24x	0.85x	0.35x	0.80x	0.72x	0.81x	0.82x	0.89x	0.06x
Interest Paid	0	0	0	1.48M	0	12.74M	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-155.6%	-72.3%	-105.85%	-343.53%	-480.5%	-122.54%
Return on Invested Capital (ROIC)	-	-	-	-880.2%	-114.71%	-228.85%	-131.61%	-74.71%	-20.93%
Gross Margin	-	-	-	-	-	-	-	-	100%
Net Margin	-	-	-	-	-	-	-	-	-49.28%
Debt / Equity	-	-	-	0.11x	0.57x	1.53x	18.69x	3.38x	6.88x
Interest Coverage	-	-56.38x	-12416.08x	-	-16.63x	-11.12x	-15.75x	-13.60x	-5.20x
FCF Conversion	-0.24x	0.85x	0.35x	0.80x	0.72x	0.81x	0.82x	0.89x	0.06x

Revenue by Segment

	2024
License and Service	90.68M
License and Service Growth	-

Frequently Asked Questions

Growth & Financials

Gossamer Bio, Inc. (GOSS) reported $44.1M in revenue for fiscal year 2024.

Gossamer Bio, Inc. (GOSS) grew revenue by 0.0% over the past year. Growth has been modest.

Gossamer Bio, Inc. (GOSS) reported a net loss of $156.2M for fiscal year 2024.

Dividend & Returns

Gossamer Bio, Inc. (GOSS) has a return on equity (ROE) of -122.5%. Negative ROE indicates the company is unprofitable.

Gossamer Bio, Inc. (GOSS) had negative free cash flow of $158.5M in fiscal year 2024, likely due to heavy capital investments.